Topics
Metastases to the CNS | Treatment | Clinical trials | Breast Cancer
Home > Publications > Topics > Metastases to the CNS > Treatment > Clinical trials > Breast Cancer
Bartsch R, Marhold M, Garde-Noguera J, Gion M, Ruiz-Borrego M,
Greil R, Valero M, Llombart-Cussac A, García-Mosquera JJ,
Arumi M, Cortés J, Campolier M, Guerrero JA, Slebe F,
Martínez-García E, Jiménez-Cortegana C,
Vaz-Batista M, Oberndorfer F, Furtner J, Fuereder T, Berghoff AS,
Preusser M.
Patritumab deruxtecan
(HER3-DXd) in patients with active brain metastases of breast
cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Lancet
Oncol. 2025 Oct 27;26(11):1467-1478. doi:
10.1016/S1470-2045(25)00470-X. PMID:
41167215. Interventional
study˰
Li
T, Zhou T, Wang B, Tao Z, Zhao M, Wang L, Jin J, Zhao Y, Gong C,
Cao J, Miao H, Peng W, Wang J, Jin M, Hu X, Zhang J.
Phase
II Clinical Study of Adebrelimab and Bevacizumab Combined With
Cisplatin/Carboplatin in Patients With Triple-Negative Breast
Cancer With Brain Metastases (ABC Study).
J
Clin Oncol.
2026 Mar 4:JCO2502021. doi:
10.1200/JCO-25-02021. PMID:
41779972.
Clinical
trials.gov
ID:
NCT04303988.
ˍ
Giordano A, Graham N, Aizer AA, Tayob N, Pereslete AM, Schoenfeld
JD, Leone JP, Davis R, Erick TK, Mayer EL, Winer EP, Krop I,
Tolaney SM, Lin NU.
A phase II study
of atezolizumab in combination with stereotactic radiation for
patients with triple-negative breast cancer and brain metastasis.
Breast
Cancer Res Treat. 2026 Mar 7;216(2):24. doi:
10.1007/s10549-026-07932-6. PMID:
41793510. Clinicaltrials.gov
ID: NCT03483012. ˍ